USFDA gives nod to Pfizer’s drug therapy for patients with Hemophilia

The USFDA has approved Hympavzi (marstacimab-hncq) for routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors. This new treatment targets a protein in the clotting process and increases the amount of thrombin, reducing or preventing bleeding episodes. Hympavzi comes with warnings for blood clots, hypersensitivity, and embryofetal toxicity.